Luckwel Pharmaceuticals Inc.: 10-Q filed 2021-09-08
What Luckwel Pharmaceuticals Inc. reported in its quarterly report filed 2021-09-08 (fiscal Q3 2021): 15 published measures, 40 facts as tagged in accession 0001493152-21-022174.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-09-08
- Fiscal period
- fiscal Q3 2021
- Accession
- 0001493152-21-022174 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Luckwel Pharmaceuticals Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-12-31 | 13,470 | USD | |
| At 2020-03-31 | 17,213 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-12-31 | 1,562,675 | USD | |
| At 2020-03-31 | 1,345,468 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-12-31 | -1,549,205 | USD | |
| At 2020-09-30 | -1,469,961 | USD | |
| At 2020-03-31 | -1,328,255 | USD | |
| At 2019-12-31 | -1,177,769 | USD | |
| At 2019-09-30 | -1,034,724 | USD | |
| At 2019-03-31 | -791,823 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-12-31 | 3,119 | USD | |
| At 2020-03-31 | 44 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-10-01 to 2020-12-31 | -79,244 | USD | 92 |
| 2020-04-01 to 2020-12-31 | -220,950 | USD | 275 |
| 2019-10-01 to 2019-12-31 | -134,045 | USD | 92 |
| 2019-04-01 to 2019-12-31 | -385,946 | USD | 275 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-04-01 to 2020-12-31 | -41,925 | USD | 275 |
| 2019-04-01 to 2019-12-31 | -250,438 | USD | 275 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-04-01 to 2020-12-31 | 45,000 | USD | 275 |
| 2019-04-01 to 2019-12-31 | 258,600 | USD | 275 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-12-31 | -3,448,723 | USD | |
| At 2020-03-31 | -3,227,773 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-10-01 to 2020-12-31 | 265 | USD | 92 |
| 2020-04-01 to 2020-12-31 | 742 | USD | 275 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-12-31 | 143,376,000 | shares | |
| At 2020-03-31 | 143,376,000 | shares | |
| At 2019-12-31 | 143,376,000 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-12-31 | 10 | USD | |
| At 2020-03-31 | 10 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-12-31 | 62,332 | USD | |
| At 2020-03-31 | 78,163 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-12-31 | 10,351 | USD | |
| At 2020-03-31 | 17,169 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-10-01 to 2020-12-31 | 78,979 | USD | 92 |
| 2020-04-01 to 2020-12-31 | 220,207 | USD | 275 |
| 2019-10-01 to 2019-12-31 | 134,045 | USD | 92 |
| 2019-04-01 to 2019-12-31 | 385,947 | USD | 275 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-10-01 to 2020-12-31 | -265 | USD | 92 |
| 2020-04-01 to 2020-12-31 | -743 | USD | 275 |
| 2019-04-01 to 2019-12-31 | 1 | USD | 275 |
Inspect the source
- Entity
- Luckwel Pharmaceuticals Inc. / CIK 0001567098
- Captured
- SEC response SHA-256
444789a3afe5c32166761a9713e1cfb92bdcb9595003c8ed59a468e3d1770909
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001567098.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))